Microdosing psychedelics is an increasingly popular phenomenon where small amounts of psychedelic drugs are taken regularly. Qualitative data have been published regarding the experiences of microdosers, but never in the context of a randomised controlled trial. Semi-structured video interviews with 40 healthy males were conducted following a double-blind placebo-controlled trial of 10 µg of...
Psychedelic-assisted interventions are emerging as potential treatments for substance use disorders, including alcohol use disorder (AUD). While recent randomized controlled trials suggest efficacy for certain psychedelics and related compounds in treating AUD, the impact of naturalistic psychedelic use on problematic alcohol consumption remains underexplored. This study examines associations...
We investigate how the dose of psilocybin truffles and participant characteristics (trait absorption and expectations) influence subjective experiences and neurophysiological outcomes in a naturalistic field setting.The aim is to replicate observed effects of psilocybin from lab-based and clinical studies in a field / naturalistic setting.
After many years of stigma and neglect, there is a resurgence of interest in the therapeutic use of psychedelic drugs. Anecdotal and evidence-based reports indicate psychedelics as a possible treatment for depression, anxiety, PTSD, substance abuse, and other disorders resistant to conventional medical interventions. The available data, however, are limited and the use of psychedelic substances...
The emergence of microdosing introduced a novel approach to consuming classic psychedelic substances, such as LSD (lysergic acid diethylamide) and psilocybin mushrooms, in ways previously unconventional. Whereas traditional illicit substance use often seeks euphoric experiences, microdosing deliberately avoids such effects in favor of perceived self-enhancing benefits. Increasingly common in...
Psychedelic treatments are considered to involve unique treatment challenges relative to other psychiatric interventions, though these are typically not explored in detail within clinical trial reports. To determine the types of challenges that providers encounter while administering psychedelic drugs in research settings and to assess provider opinions on safeguards that may be pursued to...
HealthcareOctober 23, 2025Eve E. Keighley, Eid Abo Hamza, Dalia A Bedewy et al.1 citation
Objectives: This study investigates psychedelic drugs to treat substance use disorder (SUD). Researchers have recently begun conducting clinical trials of psychedelic treatment for SUD. The current meta-analysis investigates the extent of efficacy in alleviating SM behaviours (P) using psychedelic therapy (I), concurrent with determining which psychedelic enables the greatest effect (C) as a...
Psychedelics including psilocybin, dimethyltryptamine, and lysergic acid diethylamide are known to disrupt the normal flow of time perception, for example, producing time dilation, compression, and loss of time. These temporal anomalies provide interesting clues about how the brain processes time, what consciousness is, and what produces the sense of self. This opinion article discusses the...
Substance Use Disorder (SUD) is a chronic, relapsing mental health condition characterized by compulsive substance use despite harmful consequences. According to the World Health Organization, in 2021, approximately 39.5 million individuals worldwide suffered from drug use disorders, contributing to an estimated 600,000 deaths annually. Moreover, current pharmacological treatment, such as...
Repeated self-administration of small doses of psychedelics, known as microdosing, has been associated with perceived improvements in psychological functioning. However, few studies have examined effects at the daily level. Drawing on data from a naturalistic, prospective, international survey of adults who microdose (N = 1435), we assessed self-reported within-person changes between...